10 completed, 6 recruiting, 5 active not recruiting, 4 terminated. 17 Phase 2, 8 Phase 1, 8 Phase 3, 2 Phase 4, 1 Early Phase 1.
Follow Ontruzant: new trials by email Literature Review of Ontruzant trials Research Report on Ontruzant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis Biopsy Procedure, Biospecimen Collection, Breast Conservation Treatment - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Positive Breast Carcinoma | Phase 3 | Recruiting | SWOG Cancer Research Network | 562 | 2027-03-09 | 2026-10-13 |
| Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial Biospecimen Collection, Hormone Therapy, Pembrolizumab - Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8 | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 120 | 2025-10-09 | 2026-09-24 |
| Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009) Patritumab deruxtecan, Trastuzumab, Trastuzumab Biosimilar - Breast Neoplasms, Breast Cancer | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 181 | 2025-02-26 | 2026-10-21 |
| Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study Trastuzumab, Trifluridine and Tipiracil Hydrochloride, Tucatinib - Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma | Phase 2 | Withdrawn | Academic and Community Cancer Research United | 2023-10-31 | 2024-09-19 | |
| Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma | Phase 2 | Recruiting | NRG Oncology | 146 | 2023-03-03 | 2026-08-17 |
| Evaluating Pembrolizumab, Trastuzumab and FLOT as Perioperative Treatment of HER2-positive, Localized Esophagogastric Adenocarcinoma Pembrolizumab, Trastuzumab, FLOT - Esophagogastric Adenocarcinoma | Phase 2 | Completed | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 31 | 2023-02-13 | 2026-08-10 |
| SMMART Adaptive Clinical Treatment (ACT) Trial Alectinib, Alpelisib, Anastrozole - Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm | Early Phase 1 | Withdrawn | OHSU Knight Cancer Institute | 2023-01-30 | 2024-01-23 | |
| An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis Copper Cu 64-DOTA-Trastuzumab, Magnetic Resonance Imaging, Positron Emission Tomography - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma | Phase 4 | Recruiting | City of Hope Medical Center | 10 | 2022-12-21 | 2026-07-01 |
| Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine, Paclitaxel, Trastuzumab - Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8 | Phase 2 | Recruiting | University of Washington | 25 | 2022-04-20 | 2026-05-19 |
| Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer Carboplatin, Docetaxel, Fulvestrant - Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8 | Phase 1 / Phase 2 | Active not recruiting | Jonsson Comprehensive Cancer Center | 18 | 2022-04-07 | 2026-05-11 |
| Neoadjuvant Ontruzant (SB3) in Patients With HER2-positive Early Breast Cancer: An Open-Label (NeoON) Ontruzant, Chemotherapy, Pertuzumab - Breast Cancer, Breast Neoplasms | Phase 4 | Unknown | Institut fuer Frauengesundheit | 108 | 2021-07-11 | 2023-04-18 |
| Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer Copanlisib, Pertuzumab, Trastuzumab - Anatomic Stage IV Breast Cancer AJCC v8, HER2-Positive Breast Carcinoma | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 2 | 2021-05-20 | 2025-10-01 |
| Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer Necitumumab, Osimertinib, Quality-of-Life Assessment - Metastatic Lung Non-Small Cell Carcinoma, Refractory Lung Non-Small Cell Carcinoma | Phase 1 / Phase 2 | Active not recruiting | Jonsson Comprehensive Cancer Center | 30 | 2021-01-29 | 2026-07-17 |
| Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer Alpha-tocopheryloxyacetic Acid, Trastuzumab - Anatomic Stage IV Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma | Phase 1 | Suspended | Veana Therapeutics | 24 | 2020-04-08 | 2024-07-10 |
| CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy Docetaxel, Lumpectomy, Mastectomy - Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8 | Phase 2 | Active not recruiting | ECOG-ACRIN Cancer Research Group | 2175 | 2020-03-13 | 2026-10-19 |
| TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery Multi-epitope HER2 Peptide Vaccine TPIV100, Pertuzumab, Placebo Administration - Breast Adenocarcinoma, Stage II Breast Cancer AJCC v6 and v7 | Phase 2 | Unknown | Academic and Community Cancer Research United | 480 | 2020-02-20 | 2023-12-18 |
| Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer Atezolizumab, Biopsy, Bone Scan - Metastatic Breast Adenocarcinoma, Metastatic HER2-Positive Breast Carcinoma | Phase 3 | Terminated | National Cancer Institute (NCI) | 190 | 2019-04-05 | 2026-05-29 |
| Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer Belinostat, Carfilzomib, Copanlisib Hydrochloride - Breast Adenocarcinoma, Metastatic Breast Carcinoma | Phase 1 | Terminated | Mayo Clinic | 17 | 2018-03-27 | 2025-05-26 |
| Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer Cyclophosphamide, Doxorubicin, Laboratory Biomarker Analysis - Breast Inflammatory Carcinoma, Locally Advanced Breast Carcinoma | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 34 | 2018-02-19 | 2026-02-12 |
| TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer Anastrozole, Denifanstat, Exemestane - Advanced Breast Carcinoma, HER2-Positive Breast Carcinoma | Phase 2 | Completed | Mayo Clinic | 17 | 2017-08-03 | 2026-10-09 |
Showing 20 of 30. Sign in to see all of them.
Breast Neoplasms (15) · Colonic Neoplasms (2) · Colorectal Neoplasms (2) · Esophageal Neoplasms (2) · Lung Neoplasms (2) · Ovarian Neoplasms (2) · Pancreatic Neoplasms (2) · Prostatic Neoplasms (2) · Rectal Neoplasms (2) · Adenocarcinoma Of Esophagus (1) · Brain Neoplasms (1) · Breast Neoplasms, Male (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Intraductal, Noninfiltrating (1) · Carcinoma, Non-Small-Cell Lung (1)
National Cancer Institute (NCI) (12) · Academic and Community Cancer Research United (2) · Jonsson Comprehensive Cancer Center (2) · M.D. Anderson Cancer Center (2) · Mayo Clinic (2) · City of Hope Medical Center (1) · ECOG-ACRIN Cancer Research Group (1) · Institut fuer Frauengesundheit (1) · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (1) · Merck Sharp & Dohme LLC (1) · NRG Oncology (1) · OHSU Knight Cancer Institute (1) · SWOG Cancer Research Network (1) · University of Washington (1) · Veana Therapeutics (1)
United States (27) · Canada (6) · Puerto Rico (6) · Germany (2) · South Korea (2) · Guam (1) · Ireland (1) · Israel (1) · Japan (1) · Peru (1) · South Africa (1) · United Kingdom (1)
Alan L Ho (1) · Andreas Schneeweiss, MD, Prof. (1) · Charles E Geyer (1) · Edith A Perez (1) · Gini F Fleming (1) · Grzegorz S. Nowakowski, M.D. (1) · Howard P Safran (1) · Joanne E Mortimer (1) · John H Strickler (1) · Jonathan W Goldman (1) · Keith T Flaherty (1) · Lara Davis (1) · Lisa A Carey (1) · Louis Fehrenbacher (1)
PMID 16236738, PMID 22042958, PMID 23984897, PMID 25332249, PMID 25605861, PMID 26101239, PMID 26429296, PMID 26469139, PMID 26527775, PMID 26586415, PMID 29898752, PMID 30808774, PMID 31622131, PMID 31821109, PMID 32463741, PMID 33048619, PMID 33095682, PMID 33739848, PMID 34980541, PMID 35038433, PMID 35133871, PMID 35138919, PMID 35610260, PMID 36351402, PMID 37053535, PMID 37322121, PMID 37442672, PMID 37909020, PMID 37934000, PMID 38433347, PMID 38591867, PMID 39191270, PMID 39666929, PMID 39693587, PMID 39913886, PMID 40170372, PMID 40480221, PMID 40865033, PMID 41066729, PMID 41109919, PMID 41116969, PMID 41213241, PMID 42623567
U10CA180868 (7), U10CA012027 (3), U10CA180820 (3), P30CA015083 (2), U10CA021661 (2), U10CA180821 (2), P30CA016672 (1), P30CA033572 (1), U10CA025224 (1), U10CA027469 (1), U10CA031946 (1), U10CA180830 (1), U10CA180888 (1), U24CA196172 (1), UM1CA186688 (1)